Latest Licensing Deals News

ClearVue Technologies advances its building-integrated solar tech with new product breakthroughs and global commercial projects, while strengthening its financial footing and board expertise.

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.

Weebit Nano has landed its largest customer yet with Texas Instruments licensing its ReRAM technology, while achieving key technical milestones and doubling its revenue guidance for FY26.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

AdAlta Limited has raised A$1.2 million through a strategic placement to advance its innovative PD1 armored MSLN CAR-T therapy for solid cancers, reinforcing its unique 'East to West' cellular immunotherapy approach.

Origin Energy backs a landmark US$1 billion equity raise for Kraken Technologies, valuing the company at US$8.65 billion and maintaining a significant stake as Kraken prepares to separate from Octopus Energy.

Weebit Nano has raised its FY26 revenue guidance to a minimum of $10 million following the signing of multiple IP licensing agreements with semiconductor fabs and product companies.